Sorafenib domestic price

Sorafenib (Sorafenib) is an oral multikinase inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor) that can inhibit tumor cell proliferation and tumor angiogenesis, and increase the apoptosis rate in a variety of tumor models. It can inhibit tumor cell proliferation and tumor angiogenesis, and increase the apoptosis rate in a variety of tumor models.

Sorafenib acts by inhibiting the receptor tyrosine kinase activity of the serine-threonine kinases Raf-1 and B-Raf as well as vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and platelet-derived growth factor receptor beta (PDGFR-β). Raf-1 and vascular endothelial growth factor (VEGF)-mediated cell signaling In preclinical experiments, sorafenib had antiproliferative activity in hepatocellular carcinoma cell lines and reduced tumor angiogenesis and tumor cell signaling and increased tumor cell apoptosis in a mouse xenograft model of human hepatocellular carcinoma.

The original drug of sorafenib has been launched in China and has entered the scope of medical insurance. Different regions have different reimbursement ratios, and the price after reimbursement may vary. SpecificationsThe price of 0.2g*60 tablets may be around 1,200 yuan. The original drug of sorafenib has also been launched overseas, and there are also generic drugs of sorafenib produced in other countries. The price of 0.2g*60 tablets produced by a Bangladesh pharmaceutical factory is around RMB 450 (the price may fluctuate due to the exchange rate). The ingredients of the original drug are basically the same as those of the generic drugs. For specific prices and drug details, please consult the medical consultant of Yaode.